The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Temporal trends in early-phase oncology trials in Brazil.
 
Gabriel Travessini
No Relationships to Disclose
 
Felippe Lazar
No Relationships to Disclose
 
Manuela Fonseca
No Relationships to Disclose
 
Bruna Lazar
No Relationships to Disclose
 
Elaine De Santana Longo
No Relationships to Disclose
 
Milena Mak
Honoraria - Bristol-Myers Squibb; Johnson & Johnson/Janssen; Lilly; Merck KGaA; Sanofi; United Medical
Travel, Accommodations, Expenses - Knight Pharmaceuticals
 
Laura Testa
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Novartis
Speakers' Bureau - BeOne; Daiichi Sankyo/Astra Zeneca; Lilly; Menarini; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; MSD Oncology; Roche
 
Jose Mauricio Mota
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen; Merck; Novartis; Pfizer; Zodiac Pharma
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen Oncology; Merck; Novartis; Pfizer; Zodiac Pharma
Research Funding - Bayer
Expert Testimony - Adium Pharma; Astellas Pharma; Bayer
Travel, Accommodations, Expenses - Janssen Oncology; Zodiac Pharma
 
Maria Ignez Braghiroli
Honoraria - Amgen; AstraZeneca; Bayer; BMS Brazil; Daiichi Sankyo/Astra Zeneca; Eurofarma; MSD; Takeda
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb Brazil; Johnson & Johnson/MedTech; Lilly; Merck; MSD; Roche; SERVIER; SERVIER
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb Brazil (Inst); Daiichi Sankyo/Astra Zeneca (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bayer; BMS Brazil; MSD; SERVIER
 
Maria Del Pilar Diz
No Relationships to Disclose
 
Paulo Hoff
Leadership - Oncologia D’Or
Stock and Other Ownership Interests - OncoStar
Honoraria - Bayer Health (I); United Medical (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (I); EMS; Exelixis (I); Lilly (I); United Health Group (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BMS Brazil (Inst); Exelixis (Inst); Lilly (I); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Camila Venchiarutti Moniz
Honoraria - Libbs
Consulting or Advisory Role - Aztrazenecca
Research Funding - Aztrazenecca; BMS; Immix BioPharma; Jazz Pharmaceuticals; Merck; Servier/Pfizer; Takeda
Patents, Royalties, Other Intellectual Property - “Method for treating, pharmaceutical composition, combination, kit, and use of uridine monophosphate and glutamine for treating toxicities caused by fluoropyrimidines” USPTO US 63/680,536.
Travel, Accommodations, Expenses - Amgen; Libbs; Merck